Next Article in Journal
Inflammation and Oxidative Stress in Seminal Plasma: Search for Biomarkers in Diagnostic Approach to Male Infertility
Previous Article in Journal
Clinical Utility of Personalized Serum IgG Subclass Ratios for the Differentiation of IgG4-Related Sclerosing Cholangitis (IgG4-SC) from Primary Sclerosing Cholangitis (PSC) and Cholangiocarcinoma (CCA)
Previous Article in Special Issue
Mechanistic Insights in Hemophagocytic Lymphohistiocytosis: Subsequent Acute Hepatic Failure in a Multiple Myeloma Patient Following Therapy with Ixazomib-Lenalidomide-Dexamethasone
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JPM
Volume 12
Issue 6
10.3390/jpm12060856
jpm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Identification of Genomic Variants Associated with the Risk of Acute Lymphoblastic Leukemia in Native Americans from Brazilian Amazonia

by
Luciana P. C. Leitão
1,2,†,
Darlen C. de Carvalho
1,†,
Juliana C. G. Rodrigues
1,
Marianne R. Fernandes
1,
Alayde V. Wanderley
3,
Lui W. M. S. Vinagre
1,
Natasha M. da Silva
1,
Lucas F. Pastana
1,
Laura P. A. Gellen
1,
Matheus C. E. Assunção
1,
Sweny S. M. Fernandes
3,
Esdras E. B. Pereira
4,5,
André M. Ribeiro-Dos-Santos
4,
João F. Guerreiro
4,
Ândrea Ribeiro-dos-Santos
4,
Paulo P. de Assumpção
1,
Sidney E. B. dos Santos
4 and
Ney P. C. dos Santos
1,*
1
Oncology Research Nucleus, Universidade Federal do Pará, Belém 66073-005, PA, Brazil
2
Faculdade de Ciências Médicas do Pará (FACIMPA), Marabá 68508-030, PA, Brazil
3
Pediatrics Department, Ophir Loyola Hospital, Belém 66063-240, PA, Brazil
4
Human and Medical Genetics Laboratory, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém 66075-110, PA, Brazil
5
Instituto Tocantinense Presidente Antônio Carlos (ITPAC), Abaetetuba 68440-000, PA, Brazil
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Pers. Med. 2022, 12(6), 856; https://doi.org/10.3390/jpm12060856
Submission received: 18 March 2022 / Revised: 17 April 2022 / Accepted: 18 April 2022 / Published: 25 May 2022
(This article belongs to the Special Issue Updates on Precision Medicine in Hematological Disorders)
Versions Notes

Abstract

:
A number of genomic variants related to native American ancestry may be associated with an increased risk of developing Acute Lymphoblastic Leukemia (ALL), which means that Latin American and hispanic populations from the New World may be relatively susceptible to this disease. However, there has not yet been any comprehensive investigation of the variants associated with susceptibility to ALL in traditional Amerindian populations from Brazilian Amazonia. We investigated the exomes of the 18 principal genes associated with susceptibility to ALL in samples of 64 Amerindians from this region, including cancer-free individuals and patients with ALL. We compared the findings with the data on populations representing five continents available in the 1000 Genomes database. The variation in the allele frequencies found between the different groups was evaluated using Fisher’s exact test. The analyses of the exomes of the Brazilian Amerindians identified 125 variants, seven of which were new. The comparison of the allele frequencies between the two Amerindian groups analyzed in the present study (ALL patients vs. cancer-free individuals) identified six variants (rs11515, rs2765997, rs1053454, rs8068981, rs3764342, and rs2304465) that may be associated with susceptibility to ALL. These findings contribute to the identification of genetic variants that represent a potential risk for ALL in Amazonian Amerindian populations and might favor precision oncology measures.

1. Introduction

Acute Lymphoblastic Leukemia (ALL) is the most common cancer in children and is the principal cause of childhood mortality due to malignant disease [1,2]. The genetic etiology of ALL is driven by an ample diversity of alterations of the pathways responsible for the regulation of the cell cycle in the lymphoid precursors of the B and T cell lines, which include chromosomal translocations, mutations, and aneuploidy [3,4,5]. In recent years, Genome-Wide Association Studies (GWASs) have identified a number of loci associated with the risk of developing ALL, including the ARID5B, IKZF1, PIP4K2A, CEBPE, GATA3, BMI, and CDKN2A genes [6,7,8,9,10,11].
Most GWASs addressing ALL susceptibility have focused on homogeneous populations in regions such as Europe or North America, whereas the highest incidence of childhood ALL is found in populations with a major component of native American ancestry, such as the Latin American and hispanic populations of the New World [9,12,13,14]. These populations are highly admixed and, like the population of Brazil, are primarily descended from European, African, and native American ancestors [15,16], and the high incidence of ALL observed in Latin American and hispanic populations has been attributed [9,12,13,17] to genetic risk factors related to native American ancestry. Despite the evidence that genetic variants related to native American ancestry may influence the incidence of childhood ALL, no data are available on the distribution of these variants in traditional Amerindian populations.
Given this, in the present study, we investigated the genetic variants potentially involved in the etiology of ALL in traditional Amerindian populations from Brazilian Amazonia. For this, we used New Generation Sequencing (NGS) to define the exomes of 17 genes associated with susceptibility to ALL in samples obtained from indigenous groups that inhabit Brazilian Amazonia, in both ALL patients and cancer-free individuals. The variants encountered in this initial analysis were compared with the data available on populations representing five different continents, which were obtained from the 1000 Genomes database.

2. Materials and Methods

2.1. Ethics, Consent, and Permissions

The present study was approved by Brazilian National Committee on Research Ethics—CONEP (identified by No 1062/2006 and 123/1998). All participants signed a free-informed consent as well as the tribe leaders and when necessary, a translator explained the project and the importance of the research. Their materials were collected according to the Declaration of Helsinki.

2.2. Study Population

The study sample included 59 cancer-free Amerindians and five individuals diagnosed with ALL. All the participants were members of isolated ethnic groups located in Brazilian Amazonia (Table S1). The genomic Amerindian ancestry of all these individuals was quantified and found to be at least 64% in all cases. The Amerindians with ALL were diagnosed and treated in two public hospitals specialized in the treatment of childhood cancer, the Ophir Loyola Hospital and the Octavio Lobo Childhood Oncology Hospital, both located in the city of Belém, in Pará state, northern Brazil. The clinical and demographic data on these patients are presented in Table S2.
Data were obtained from the 1000 Genomes Project database (available at https://www.1000genomes.org, accessed on: 20 February 2021) to provide comparisons with ethnic groups from other continents. This sample included 661 individuals from Africa (AFR), 503 from Europe (EUR), 347 from the Americas (AMR), 504 from East Asia (EAS), and 489 from South Asia (SAS).

2.3. Selection of the Genes

A total of 17 genes were selected for the present study (see Table S3). The genes were selected based on a search of the literature available in the NCBI and Ensembl databases, and on GWASs or studies of other genetic markers associated with the risk of ALL. More details are described in Table S4.

2.4. Extraction of the DNA and Preparation of the Exomes

Samples of 5 mL of peripheral blood were collected from each of the participants of the study. The genetic material was extracted from these blood samples using the Roche Applied Science DNA extraction kit (Roche, Penzberg, Germany) following the manufacturer’s instructions, and it was quantified using a NanoDrop 1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The exome libraries were prepared using the commercial Nextera Rapid Capture Exome kit (Illumina, San Diego, CA, EUA) and the SureSelect Human All Exon V6 kit (Agilent, Santa Clara, CA, USA), with the manufacturer’s protocol being followed in both cases. The sequencing reactions were run in the NextSeq 500® platform (Illumina®, San Diego, CA, USA) using the NextSeq 500 high-output v2 300 cycle kit (Illumina®, San Diego, CA, USA).

2.5. Bioinformatic Analysis

The bioinformatic analyses followed the approach described by Ribeiro-Dos-Santos et al. [18] and Rodrigues et al. [19]. For this, the sequences were first filtered to eliminate low-quality reads, and then mapped and aligned with the reference genome (GRCh38) using BWA v.0.7. The alignment was then processed to remove duplicate sequences, recalibrate the mapping quality, and finalize local realignment. The results were processed in GATK v.3.2 to identify the reference genome variants. The Viewer of Variants (ViVa®, Universidade Federal do Rio Grande do Norte, Natal, RN, Brazil) software was used to analyze the annotations of the variants. The variants were annotated in three databases—SnpEff v.4.3.T, Ensembl Variant Effect Predictor (Ensembl version 99), and ClinVar (v.2018–10). The SIFT (v.6.2.1), PolyPhen-2 (v.2.2), LRT (November, 2009), Mutation Assessor (v.3.0), Mutation Taster (v.2.0), FATHMM (v.2.3), PROVEAN (v.1.1.3), MetaSVM (v.1.0), M-CAP (v.1.4), and FATHMM-MKL databases were used for the in silico prediction of pathogenicity.

2.6. Statistical Analysis

For the statistical analyses, the cancer-free Amerindians were assigned to the Native (NAT) group, while the ALL patients were in the ALL_NAT (Native with ALL) group. All the analyses were run in the R v.3.5.1 program. The differences in the allelic frequencies between the NAT and ALL_NAT were evaluated using Fisher’s exact test, which was also applied to the comparisons with the continental populations. A p ≤ 0.05 significance level was considered for all the analyses.

3. Results

The analysis of the exomes of the 64 Amerindians investigated in the present study revealed the presence of 125 variants, seven of which were new. The SnpEff software [20] was used to annotate and predict the effects of these variants. This procedure classifies the impact of the variants in four categories: (i) modifier (no evidence of impact), (ii) low (no apparent alteration of protein function), (iii) moderate (some alteration of protein function), and (iv) high (high level of impact on protein function). The 118 variants identified in the 17 genes investigated in the present study are described in Table S3. Four of the new variants were classified as modifiers (Table 1), two as low effect, and one as moderate. The majority of these new variants were found in the ALL_NAT group, at frequencies of less than 0.1%.
As some of the variants were not covered adequately in one or other of the groups (NAT or ALL_NAT), they were excluded from the comparison of allele frequencies. This left 64 variants that were included in the analysis of association. The frequencies of these variants are compared between groups in Table 2.
The analyses revealed significant differences between the two groups in six variants of five genes: PIP4K2A (variants rs2765997 and rs1053454), CDKN2A (rs11515), IGF2BP1 (rs8068981), USP7 (rs2304465), and WWOX (rs3764342). The allele frequencies of these six variants recorded in the ALL_NAT group were also compared with those recorded in the 1000 Genomes Project for the five continental populations (AFR, AMR, EAS, EUR, and SAS). The comparisons are shown in Table 3 and the p values, in Table 4.
The analyses revealed significant differences between the Amerindian group (ALL_NAT) and all the continental populations (AFR, AMR, EAS, EUR and SAS) in the frequency of the rs11515 variant of the CDKN2A gene. The frequency of the rs8068981 variant of the IGF2BP1 gene was also significantly different from that of the EAS population, while the frequency of the rs2765997 variant of the PIP4K2A gene was significantly different from those of the AFR and EAS populations.

4. Discussion

The incidence of ALL is relatively high in populations with a high degree of native American ancestry, such as Latin American and Hispanic populations, which has been attributed, in part, to the contribution of molecular markers associated with a high risk of ALL in these populations [9,12,13,14,21]. Despite this known association, no genomic data are available on the susceptibility to ALL of traditional Amerindian populations from Brazilian Amazonia. In the present study, we investigated the exomes of 17 of the principal genes associated with susceptibility to ALL in samples of indigenous Amazonian populations, including ALL patients and cancer-free individuals. It would be interesting to demonstrate whether the results observed for the markers investigated here in Amerindian populations would demonstrate the same profile in a larger cohort of leukemic patients from the same ethnic group. However, samples from indigenous patients with ALL are difficult to obtain, given the rarity of the disease and due to the fact that these populations inhabit remote and difficult-to-access rural regions, which reflects on the difficulty of care and clinical follow-up of these patients.
During the study, we identified seven new variants in four genes (IKZF1, IKZF3, WWOX, and ZPBP2), most of which were present in the ALL_NAT group, that is, Amerindian ALL patients. These genes are known to have alleles associated with some level of risk in the etiology of ALL in different populations [17,22,23,24]. Given this, we believe that the new variants identified in the present study should be investigated further as potential risk factors for the incidence of ALL in Amerindian populations.
We also identified six variants of five genes that we associated with susceptibility to ALL (CDKN2A_rs11515, PIP4K2A_rs2765997 and rs1053454, IGF2BP1_rs8068981, WWOX_ rs3764342, and USP7_rs2304465) given the significant differences in the frequencies recorded in the two Amerindian groups (ALL patients and cancer-free individuals), and between the ALL group and populations of other groups from around the world.
The CDKN2A gene plays an important role in leukemogenesis. The rs11515 variant is located in the 3′-untranslated region (UTR) of the CDKN2A gene, and is known to be associated with a number of different types of cancer [25], including breast cancer [26], glioblastoma [27], melanoma [28], and colorectal cancer [29]. However, no data are available on the possible influence of this variant on the risk of developing ALL. In the present study, we recorded a high frequency of this variant in the Amerindian population, which was significantly higher than that recorded in other populations around the world. This indicates that research on this variant should be prioritized for the identification of its potential role in the etiology of ALL in this population.
A number of previous studies of genetic polymorphisms in the PIP4K2A gene have identified an association with susceptibility to ALL [30,31]. We identified an association with ALL in two variants (rs2765997 and rs105334534) of the PIP4K2A gene, given that both were more frequent in the Amerindian population, in comparison with the other continental populations, which may reflect a potential correlation with the risk of ALL.
The IGF2BP1 protein is expressed in a number of different types of cancer, including leukemia. In a recent study based on in vivo and in vitro analyses, Elcheva et al. [32] found evidence of a significant correlation between IGF2BP1 and the aggressiveness of leukemia, through the persistence of tumorigenicity by increasing critical transcriptional and metabolic regulators. These authors also emphasized that the IGF2BP1 gene is often positively regulated in many types of malignant disease, and is not expressed in most normal tissue, which means that it is a potentially important target for anticancer therapy. The results of the present study indicate that the rs8068981 variant of the IGF2BP1 gene is present at similar frequencies in the Amerindians with ALL and the European population, but contrasts with the Asian populations.
We also identified in the Amerindian population a positive association with the rs3764342 variant of the WWOX gene, which has a suppressor role in solid cancers, with the loss of function resulting in alterations in the adhesion of the cancerous cells to the extra-cellular matrix, which affects cell migration and metastasis. A number of studies have contributed to the description of the role of this gene in leukemic malignancies. Luo et al. [33] found that the expression of the WWOX mRNA and protein is significantly reduced or absent in cases of leukemia and their cell lines in comparison with the controls, which is consistent with the findings of Cui et al. [34], who evaluated patients diagnosed with different types of leukemia.
In the present study, the rs2304465 variant of the USP7 gene was also more frequent in Amerindian patients. Jin et al. [35] found an association between USP7 and a lack of ubiquitination and the stabilization of the NOTCH1 oncogene, which contributes to the control of the cell growth of the T cells in lymphoblastic leukemia.

5. Conclusions

The present study is the first to investigate the exome of genes involved in the etiology of Acute Lymphoblastic Leukemia (ALL) in Amerindian populations from the Amazon region. The results of the study provide important genetic data related to the etiology of ALL in such population in which genetic investigations are scarce. The study also contributes to the identification of variants of potential risk involved in the etiology of ALL in Amerindian populations, as well as in other Brazilian populations formed through a high level of admixture with this indigenous group.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jpm12060856/s1, Table S1. Names and the number of individuals in each population group analyzed in the present study; Table S2. Epidemiological and clinical characteristics of the patients included in the study; Table S3. Description of the variants found in the Amerindian population investigated in the present study; Table S4 [36,37,38,39,40,41,42,43,44,45,46,47,48]. Description of the studies selected to choose the genes studied.

Author Contributions

All the authors contributed significantly to the preparation of the manuscript: L.P.C.L. and D.C.d.C. collected and analyzed the data and wrote the text; M.R.F., A.V.W., L.W.M.S.V., N.M.d.S., L.F.P., L.P.A.G., M.C.E.A., S.S.M.F., E.E.B.P., A.M.R.-D.-S. and J.C.G.R. collected and analyzed the data, ran the statistical analyses, and revised the manuscript; J.F.G., Â.R.-d.-S., P.P.d.A., S.E.B.d.S. and N.P.C.d.S. reviewed the statistical analyses, and edited and approved the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (http://www.cnpq.br), the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) (https://www.gov.br/capes/pt-br), the Pró-Reitoria de Pesquisa e Pós-Graduação da UFPA (PROPESP) (http://www.propesp.ufpa.br), and the Fundação Amazônia de Amparo a Estudos e Pesquisas (FAPESPA) (http://www.fapespa.pa.gov.br). This work is part of the Rede de Pesquisa em Genômica Populacional Humana (Biocomputacional-Protocol no. 3381/2013/CAPES).

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Brazilian National Commission for Ethics in Research (CONEP) and by the Research Ethics Committee of the UFPA Tropical Medicine Center, under authorization CAAE-20654313.6.0000.5172.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Not applicable.

Acknowledgments

We acknowledge the Universidade Federal do Pará (UFPA); Oncology Research Center (NPO/UFPA); Postgraduate Program in Genetics and Molecular Biology (PPGBM/UFPA); Human and Medical Genetics Laboratory (LGHM/UFPA); Postgraduate Program in Oncology and Medical Science (PPGOCM/NPO). Ney Santos is supported by CNPq/Produtividade (CNPQ 309999/2021-9).

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Pui, C.-H.; Carroll, W.L.; Meshinchi, S.; Arceci, R.J. Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update. J. Clin. Oncol. 2011, 29, 551–565. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Bagnasco, F.; Caruso, S.; Andreano, A.; Valsecchi, M.G.; Jankovic, M.; Biondi, A.; Miligi, L.; Casella, C.; Terenziani, M.; Massimino, M.; et al. Late Mortality and Causes of Death among 5-Year Survivors of Childhood Cancer Diagnosed in the Period 1960–1999 and Registered in the Italian Off-Therapy Registry. Eur. J. Cancer 2019, 110, 86–97. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Hunger, S.P.; Mullighan, C.G. Acute Lymphoblastic Leukemia in Children. N. Engl. J. Med. 2015, 373, 1541–1552. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Mullighan, C.G.; Goorha, S.; Radtke, I.; Miller, C.B.; Coustan-Smith, E.; Dalton, J.D.; Girtman, K.; Mathew, S.; Ma, J.; Pounds, S.B.; et al. Genome-Wide Analysis of Genetic Alterations in Acute Lymphoblastic Leukaemia. Nature 2007, 446, 758–764. [Google Scholar] [CrossRef] [PubMed]
  5. Coccaro, N.; Anelli, L.; Zagaria, A.; Specchia, G.; Albano, F. Next-Generation Sequencing in Acute Lymphoblastic Leukemia. Int. J. Mol. Sci. 2019, 20, 2929. [Google Scholar] [CrossRef] [Green Version]
  6. Papaemmanuil, E.; Hosking, F.J.; Vijayakrishnan, J.; Price, A.; Olver, B.; Sheridan, E.; Kinsey, S.E.; Lightfoot, T.; Roman, E.; Irving, J.A.E.; et al. Loci on 7p12.2, 10q21.2 and 14q11.2 Are Associated with Risk of Childhood Acute Lymphoblastic Leukemia. Nat. Genet. 2009, 41, 1006–1010. [Google Scholar] [CrossRef] [Green Version]
  7. Treviño, L.R.; Yang, W.; French, D.; Hunger, S.P.; Carroll, W.L.; Devidas, M.; Willman, C.; Neale, G.; Downing, J.; Raimondi, S.C.; et al. Germline Genomic Variants Associated with Childhood Acute Lymphoblastic Leukemia. Nat. Genet. 2009, 41, 1001–1005. [Google Scholar] [CrossRef] [Green Version]
  8. Perez-Andreu, V.; Roberts, K.G.; Harvey, R.C.; Yang, W.; Cheng, C.; Pei, D.; Xu, H.; Gastier-Foster, J.; Shuyu, E.; Lim, J.Y.-S.; et al. Inherited GATA3 Variants Are Associated with Ph-like Childhood Acute Lymphoblastic Leukemia and Risk of Relapse. Nat. Genet. 2013, 45, 1494–1498. [Google Scholar] [CrossRef] [Green Version]
  9. Xu, H.; Yang, W.; Perez-Andreu, V.; Devidas, M.; Fan, Y.; Cheng, C.; Pei, D.; Scheet, P.; Burchard, E.G.; Eng, C.; et al. Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. JNCI J. Natl. Cancer Inst. 2013, 105, 733–742. [Google Scholar] [CrossRef] [Green Version]
  10. Moriyama, T.; Relling, M.V.; Yang, J.J. Inherited Genetic Variation in Childhood Acute Lymphoblastic Leukemia. Blood 2015, 125, 3988–3995. [Google Scholar] [CrossRef] [Green Version]
  11. Vijayakrishnan, J.; Studd, J.; Broderick, P.; Kinnersley, B.; Holroyd, A.; Law, P.J.; Kumar, R.; Allan, J.M.; Harrison, C.J.; Moorman, A.V.; et al. Genome-Wide Association Study Identifies Susceptibility Loci for B-Cell Childhood Acute Lymphoblastic Leukemia. Nat. Commun. 2018, 9, 1340. [Google Scholar] [CrossRef] [PubMed]
  12. Yamamoto, J.F.; Goodman, M.T. Patterns of Leukemia Incidence in the United States by Subtype and Demographic Characteristics, 1997–2002. Cancer Causes Control. 2008, 19, 379–390. [Google Scholar] [CrossRef] [PubMed]
  13. Walsh, K.M.; Chokkalingam, A.P.; Hsu, L.-I.; Metayer, C.; de Smith, A.J.; Jacobs, D.I.; Dahl, G.V.; Loh, M.L.; Smirnov, I.V.; Bartley, K.; et al. Associations between Genome-Wide Native American Ancestry, Known Risk Alleles and B-Cell ALL Risk in Hispanic Children. Leukemia 2013, 27, 2416–2419. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Quiroz, E.; Aldoss, I.; Pullarkat, V.; Rego, E.; Marcucci, G.; Douer, D. The Emerging Story of Acute Lymphoblastic Leukemia among the Latin American Population—Biological and Clinical Implications. Blood Rev. 2019, 33, 98–105. [Google Scholar] [CrossRef] [PubMed]
  15. Santos, N.P.C.; Ribeiro-Rodrigues, E.M.; Ribeiro-dos-Santos, Â.K.C.; Pereira, R.; Gusmão, L.; Amorim, A.; Guerreiro, J.F.; Zago, M.A.; Matte, C.; Hutz, M.H.; et al. Assessing Individual Interethnic Admixture and Population Substructure Using a 48-Insertion-Deletion (INSEL) Ancestry-Informative Marker (AIM) Panel. Hum. Mutat. 2010, 31, 184–190. [Google Scholar] [CrossRef]
  16. Secolin, R.; Mas-Sandoval, A.; Arauna, L.R.; Torres, F.R.; de Araujo, T.K.; Santos, M.L.; Rocha, C.S.; Carvalho, B.S.; Cendes, F.; Lopes-Cendes, I.; et al. Distribution of Local Ancestry and Evidence of Adaptation in Admixed Populations. Sci. Rep. 2019, 9, 13900. [Google Scholar] [CrossRef] [Green Version]
  17. Wiemels, J.L.; Walsh, K.M.; de Smith, A.J.; Metayer, C.; Gonseth, S.; Hansen, H.M.; Francis, S.S.; Ojha, J.; Smirnov, I.; Barcellos, L.; et al. GWAS in Childhood Acute Lymphoblastic Leukemia Reveals Novel Genetic Associations at Chromosomes 17q12 and 8q24.21. Nat. Commun. 2018, 9, 286. [Google Scholar] [CrossRef] [Green Version]
  18. Ribeiro-Dos-Santos, A.M.; Vidal, A.F.; Vinasco-Sandoval, T.; Guerreiro, J.; Santos, S.; Ribeiro-Dos-Santos, Â.; de Souza, S.J. Exome Sequencing of Native Populations From the Amazon Reveals Patterns on the Peopling of South America. Front. Genet. 2020, 11, 548507. [Google Scholar] [CrossRef]
  19. Rodrigues, J.C.G.; de Souza, T.P.; Pastana, L.F.; Ribeiro dos Santos, A.M.; Fernandes, M.R.; Pinto, P.; Wanderley, A.V.; de Souza, S.J.; Kroll, J.E.; Pereira, A.L.; et al. Identification of NUDT15 Gene Variants in Amazonian Amerindians and Admixed Individuals from Northern Brazil. PLoS ONE 2020, 15, e0231651. [Google Scholar] [CrossRef] [Green Version]
  20. Cingolani, P.; Platts, A.; Wang, L.L.; Coon, M.; Nguyen, T.; Wang, L.; Land, S.J.; Lu, X.; Ruden, D.M. A Program for Annotating and Predicting the Effects of Single Nucleotide Polymorphisms, SnpEff. Fly 2012, 6, 80–92. [Google Scholar] [CrossRef] [Green Version]
  21. Shoag, J.M.; Barredo, J.C.; Lossos, I.S.; Pinheiro, P.S. Acute Lymphoblastic Leukemia Mortality in Hispanic Americans. Leuk. Lymphoma 2020, 61, 2674–2681. [Google Scholar] [CrossRef] [PubMed]
  22. Churchman, M.L.; Qian, M.; te Kronnie, G.; Zhang, R.; Yang, W.; Zhang, H.; Lana, T.; Tedrick, P.; Baskin, R.; Verbist, K.; et al. Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell 2018, 33, 937–948.e8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Hong, Y.; Wang, Q.; Song, Y.L.; Liu, G.M.; Yang, X.; Yan, M.X. Relationship between IKZF3 Gene Single Nucleotide Polymorphisms and Childhood Acute Lymphoblastic Leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021, 29, 690–695. [Google Scholar] [CrossRef] [PubMed]
  24. Shi, Y.; Du, M.; Fang, Y.; Tong, N.; Zhai, X.; Sheng, X.; Li, Z.; Xue, Y.; Li, J.; Chu, H.; et al. Identification of a Novel Susceptibility Locus at 16q23.1 Associated with Childhood Acute Lymphoblastic Leukemia in Han Chinese. Hum. Mol. Genet. 2016, 25, 2873–2880. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Dong, Y.; Wang, X.; Yang, Y.-W.; Liu, Y.-J. The Effects of CDKN2A Rs3731249, Rs11515, and Rs3088440 Polymorphisms on Cancer Risk. Cell. Mol. Biol. 2017, 63, 40. [Google Scholar] [CrossRef] [PubMed]
  26. Royds, J.A.; Pilbrow, A.P.; Ahn, A.; Morrin, H.R.; Frampton, C.; Russell, I.A.; Moravec, C.S.; Sweet, W.E.; Tang, W.H.W.; Currie, M.J.; et al. The Rs11515 Polymorphism Is More Frequent and Associated with Aggressive Breast Tumors with Increased ANRIL and Decreased P16INK4a Expression. Front. Oncol. 2016, 5, 306. [Google Scholar] [CrossRef]
  27. Sibin, M.K.; Dhananjaya, I.B.; Narasingarao, K.V.L.; Harshitha, S.M.; Jeru-Manoj, M.; Chetan, G.K. Two Gene Polymorphisms (Rs4977756 and Rs11515) in CDKN2A/B and Glioma Risk in South Indian Population. Meta Gene 2016, 9, 215–218. [Google Scholar] [CrossRef] [Green Version]
  28. Sauroja, I.; Smeds, J.; Vlaykova, T.; Kumar, R.; Talve, L.; Hahka-Kemppinen, M.; Punnonen, K.; Jansèn, C.T.; Hemminki, K.; Pyrhönen, S. Analysis of G1/S Checkpoint Regulators in Metastatic Melanoma. Genes Chromosomes Cancer 2000, 28, 404–414. [Google Scholar] [CrossRef]
  29. McCloud, J.; Sivakumar, R.; Greenhough, A.; Elder, J.; Jones, P.; Deakin, M.; Elder, J.; Fryer, A.; Hoban, P. P16INK4a Polymorphism: Associations with Tumour Progression in Patients with Sporadic Colorectal Cancer. Int. J. Oncol. 2004, 25, 1447–1452. [Google Scholar] [CrossRef]
  30. Liao, F.; Yin, D.; Zhang, Y.; Hou, Q.; Zheng, Z.; Yang, L.; Shu, Y.; Xu, H.; Li, Y. Association Between PIP4K2A Polymorphisms and Acute Lymphoblastic Leukemia Susceptibility. Medicine 2016, 95, e3542. [Google Scholar] [CrossRef]
  31. Zhou, X.; Liao, F.; Zhang, J.; Qin, Y.; Xu, H.; Ding, Z.; Zhang, Y.; Zhang, F. Association of the Independent Polymorphisms in CDKN2A with Susceptibility of Acute Lymphoblastic Leukemia. Biosci. Rep. 2018, 38. [Google Scholar] [CrossRef] [PubMed]
  32. Elcheva, I.A.; Wood, T.; Chiarolanzio, K.; Chim, B.; Wong, M.; Singh, V.; Gowda, C.P.; Lu, Q.; Hafner, M.; Dovat, S.; et al. RNA-Binding Protein IGF2BP1 Maintains Leukemia Stem Cell Properties by Regulating HOXB4, MYB, and ALDH1A1. Leukemia 2020, 34, 1354–1363. [Google Scholar] [CrossRef] [PubMed]
  33. Luo, L.; Chen, Y.; Cheng, X.; Lin, Y.; Fu, X.; Li, D.; Cui, Z.; Lin, D. Reduced Expression of the WW Domain-Containing Oxidoreductase in Human Hematopoietic Malignancies. Oncol. Lett. 2016, 11, 4083–4088. [Google Scholar] [CrossRef] [Green Version]
  34. Cui, Z.; Lin, D.; Cheng, F.; Luo, L.; Kong, L.; Xu, J.; Hu, J.; Lan, F. The Role of the WWOX Gene in Leukemia and Its Mechanisms of Action. Oncol. Rep. 2013, 29, 2154–2162. [Google Scholar] [CrossRef] [Green Version]
  35. Jin, Q.; Martinez, C.A.; Arcipowski, K.M.; Zhu, Y.; Gutierrez-Diaz, B.T.; Wang, K.K.; Johnson, M.R.; Volk, A.G.; Wang, F.; Wu, J.; et al. USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia. Clin. Cancer Res. 2019, 25, 222–239. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Hao, Q.; Cao, M.; Zhang, C.; Yin, D.; Wang, Y.; Ye, Y.; Zhao, S.; Yang, Y.; Chen, K.-L.; Ying, B.; et al. Age-related differences of genetic susceptibility to patients with acute lymphoblastic leukemia. Aging 2021, 13, 12456–12465. [Google Scholar] [CrossRef] [PubMed]
  37. Perez-Andreu, V.; Roberts, K.G.; Xu, H.; Smith, C.; Zhang, H.; Yang, W.; Harvey, R.C.; Payne-Turner, D.; Devidas, M.; Cheng, I.-M.; et al. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood 2015, 125, 680–686. [Google Scholar] [CrossRef] [Green Version]
  38. Urayama, K.Y.; Takagi, M.; Kawaguchi, T.; Matsuo, K.; Tanaka, Y.; Ayukawa, Y.; Arakawa, Y.; Hasegawa, D.; Yuza, Y.; Kaneko, T.; et al. Regional evaluation of childhood acute lymphoblastic leukemia genetic susceptibility loci among Japanese. Sci. Rep. 2018, 8, 789. [Google Scholar] [CrossRef]
  39. Semmes, E.C.; Vijayakrishnan, J.; Zhang, C.; Hurst, J.H.; Houlston, R.S.; Walsh, K.M. Leveraging Genome and Phenome-Wide Association Studies to Investigate Genetic Risk of Acute Lymphoblastic Leukemia. Cancer Epidemiol. Biomarkers Prev. 2020, 29, 1606–1614. [Google Scholar] [CrossRef]
  40. Vijayakrishnan, J.; Qian, M.; Studd, J.B.; Yang, W.; Kinnersley, B.; Law, P.J.; Broderick, P.; Raetz, E.A.; Allan, J.; Pui, C.-H.; et al. Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. Nat. Commun. 2019, 10, 1–9. [Google Scholar] [CrossRef] [Green Version]
  41. Brown, A.L.; de Smith, A.J.; Gant, V.U.; Yang, W.; Scheurer, M.E.; Walsh, K.M.; Chernus, J.M.; Kallsen, N.A.; Peyton, S.A.; Davies, G.E.; et al. Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. Blood 2019, 134, 1227–1237. [Google Scholar] [CrossRef] [PubMed]
  42. Sherborne, A.; Hosking, F.; Prasad, R.; Kumar, R.; Koehler, R.; Vijayakrishnan, J.; Papaemmanuil, E.; Bartram, C.R.; Stanulla, M.; Schrappe, M.; et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat. Genet. 2010, 42, 492–494. [Google Scholar] [CrossRef]
  43. Hungate, E.A.; Vora, S.R.; Gamazon, E.; Moriyama, T.; Best, T.; Hulur, I.; Lee, Y.; Evans, T.-J.; Ellinghaus, E.; Stanulla, M.; et al. A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. Nat. Commun. 2016, 7, 10635. [Google Scholar] [CrossRef] [Green Version]
  44. Liao, F.; Ye, Y.; Yin, D.; Qin, Y.; Zhao, J.; Zhang, W.; Zhang, Y.; Deng, Z.; Wang, Y.; Ying, B.; et al. Validations of Top and Novel Susceptibility Variants in All-Age Chinese Patients With Acute Lymphoblastic Leukemia. Front. Genet. 2020, 11, 1004. [Google Scholar] [CrossRef] [PubMed]
  45. Al-Absi, B.; Razif, M.F.M.M.F.; Noor, S.M.S.M.; Saif-Ali, R.; Aqlan, M.; Salem, S.D.S.D.; Ahmed, R.H.R.H.; Muniandy, S. Contributions of IKZF1, DDC, CDKN2A, CEBPE, and LMO1 Gene Polymorphisms to Acute Lymphoblastic Leukemia in a Yemeni Population. Genet. Test. Mol. Biomark. 2017, 21, 592–599. [Google Scholar] [CrossRef] [PubMed]
  46. Vijayakrishnan, J.; Kumar, R.; Henrion, M.Y.R.; Moorman, A.V.; Rachakonda, P.S.; Hosen, I.; Filho, M.I.D.S.; Holroyd, A.; E Dobbins, S.; Koehler, R.; et al. A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1. Leukemia 2016, 31, 573–579. [Google Scholar] [CrossRef] [Green Version]
  47. Zhang, H.; Liu, A.P.-Y.; Devidas, M.; Lee, S.H.; Cao, X.; Pei, D.; Borowitz, M.; Wood, B.; Gastier-Foster, J.M.; Dai, Y.; et al. Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. JNCI: J. Natl. Cancer Inst. 2020, 113, 408–417. [Google Scholar] [CrossRef]
  48. Qian, M.; Zhao, X.; Devidas, M.; Yang, W.; Gocho, Y.; Smith, C.; Gastier-Foster, J.M.; Li, Y.; Xu, H.; Zhang, S.; et al. Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children. JNCI: J. Natl. Cancer Inst. 2019, 111, 1350–1357. [Google Scholar] [CrossRef]
Table
Table 1. The new gene variants identified in the Amerindian population investigated in the present study.
Table 1. The new gene variants identified in the Amerindian population investigated in the present study.
ChromosomeChromosomal PositionGeneImpactReference AlleleGroup
chr750368329IKZF1MODIFIERCALL_NAT
chr1678108386WWOXMODIFIERTALL_NAT
chr1678386853WWOXLOWANAT
chr1739832190IKZF3MODIFIERTNAT
chr1739765793IKZF3MODERATECALL_NAT
chr1739868422ZPBP2MODIFIERCALL_NAT
chr1739765799IKZF3LOWCALL_NAT
Table
Table 2. Comparisons of the frequencies of the alleles investigated in the present study between the two Amerindian groups, that is, ALL patients (ALL_NAT) and cancer-free individuals (NAT).
Table 2. Comparisons of the frequencies of the alleles investigated in the present study between the two Amerindian groups, that is, ALL patients (ALL_NAT) and cancer-free individuals (NAT).
Frequency in Group:
dbSNPGeneALL_NATNAT* p
rs773061413ARID5B0.2000.0781
rs513349BAK10.800.560.3868
rs11515CDKN2A0.6010.0050
rs3088440CDKN2A0.500.561
rs974336CDKN2B0.2500.0781
rs2302901ELK300.031
rs422628GATA30.750.970.2197
rs2305479GSDMB0.300.431
rs2305480GSDMB0.300.431
rs11078928GSDMB0.300.431
rs12450091GSDMB0.200.261
rs11078927GSDMB0.300.421
rs8068981IGF2BP10.6000.0002
rs62078405IGF2BP10.2000.0781
rs2289637IGF2BP10.200.060.3434
rs10899750IKZF10.500.670.6572
rs61731355IKZF10.200.311
rs12669559IKZF10.100.281
rs907092IKZF30.200.040.2197
rs3824810LHPP0.600.571
rs3824809LHPP0.600.710.6287
rs6597801LHPP0.700.880.1907
rs943192PIP4K2A0.800.980.1513
rs2765997PIP4K2A0.500.960.0043
rs1132816PIP4K2A0.100.010.1774
rs61731109PIP4K2A0.100.010.1774
rs1053454PIP4K2A0.9007.264 × 10−7
rs2447919USP70.130.311
rs11551182USP70.300.401
rs139138924USP7111
rs2304465USP70.4000.0050
rs1382390USP71.0011
rs2447918USP70.1600.0781
rs117832776WWOX0.2000.0781
rs383362WWOX0.300.160.3052
rs77897021WWOX0.100.080.4545
rs12934985WWOX0.100.211
rs3764342WWOX0.4000.0050
rs200461412WWOX0.200.030.2197
rs140060332WWOX0.2000.0781
rs4130513WWOX0.300.090.1551
rs11545029WWOX0.100.080.4545
rs8050128WWOX0.750.410.1590
rs75559202WWOX0.100.090.4545
rs146481440WWOX0.200.060.3434
rs12446823WWOX0.100.010.1774
rs2288034WWOX0.600.320.3292
rs144601717WWOX0.100.010.1774
rs2303190WWOX00.220.5739
rs3764340WWOX0.200.090.3990
rs2303191WWOX0.800.980.1513
rs2288035WWOX0.100.080.4545
rs8048830WWOX0.250.010.1513
rs67493355WWOX0.250.161
rs202093359WWOX0.200.080.3990
rs11545028WWOX0.100.221
rs2288033WWOX0.400.250.5917
rs7199110WWOX0.600.400.6423
rs555396422WWOX0.1000.0923
rs384216WWOX001
rs75027016ZPBP20.300.150.2662
rs11557467ZPBP20.300.431
rs11557466ZPBP20.300.421
rs10852935ZPBP20.300.431
* Fisher’s exact test.
Table
Table 3. Allele frequencies of the six key variants identified in the present study in the ALL_NAT populations (Table 2) and the five continental populations from the 1000 Genomes Project (AFR, AMR, EAS, EUR, and SAS).
Table 3. Allele frequencies of the six key variants identified in the present study in the ALL_NAT populations (Table 2) and the five continental populations from the 1000 Genomes Project (AFR, AMR, EAS, EUR, and SAS).
dbSNPGeneFrequency in the Population:
ALL_NATAFRAMREASEURSAS
rs11515CDKN2A0.600.160.080.020.150.05
rs8068981IGF2BP10.600.570.680.950.710.82
rs2765997PIP4K2A0.500.180.200.050.370.37
rs1053454PIP4K2A0.900.850.810.650.640.78
rs2304465USP70.400.660.580.700.590.49
rs3764342WWOX0.400.550.140.300.110.32
Table
Table 4. The p values recorded for the pairwise comparisons (ALL_NAT vs. AFR, AMR, EAS, EUR or SAS) of the allele frequencies of the six key variants identified in the present study (see Table 3).
Table 4. The p values recorded for the pairwise comparisons (ALL_NAT vs. AFR, AMR, EAS, EUR or SAS) of the allele frequencies of the six key variants identified in the present study (see Table 3).
dbSNPGeneFrequency ALL_NATp for the ALL_NAT Population Versus:
AFRAMREASEURSAS
rs11515CDKN2A0.670.03490.00500.00010.02670.0015
rs8068981IGF2BP10.6010.65770.02630.62830.2302
rs2765997PIP4K2A0.500.04520.05790.00150.36270.3663
rs1053454PIP4K2A0.9010.58800.17020.16550.5911
rs2304465USP70.400.34470.65350.16020.65361
rs3764342WWOX0.400.66260.15950.64110.09600.6550
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Leitão, L.P.C.; de Carvalho, D.C.; Rodrigues, J.C.G.; Fernandes, M.R.; Wanderley, A.V.; Vinagre, L.W.M.S.; da Silva, N.M.; Pastana, L.F.; Gellen, L.P.A.; Assunção, M.C.E.; et al. Identification of Genomic Variants Associated with the Risk of Acute Lymphoblastic Leukemia in Native Americans from Brazilian Amazonia. J. Pers. Med. 2022, 12, 856. https://doi.org/10.3390/jpm12060856

AMA Style

Leitão LPC, de Carvalho DC, Rodrigues JCG, Fernandes MR, Wanderley AV, Vinagre LWMS, da Silva NM, Pastana LF, Gellen LPA, Assunção MCE, et al. Identification of Genomic Variants Associated with the Risk of Acute Lymphoblastic Leukemia in Native Americans from Brazilian Amazonia. Journal of Personalized Medicine. 2022; 12(6):856. https://doi.org/10.3390/jpm12060856

Chicago/Turabian Style

Leitão, Luciana P. C., Darlen C. de Carvalho, Juliana C. G. Rodrigues, Marianne R. Fernandes, Alayde V. Wanderley, Lui W. M. S. Vinagre, Natasha M. da Silva, Lucas F. Pastana, Laura P. A. Gellen, Matheus C. E. Assunção, and et al. 2022. "Identification of Genomic Variants Associated with the Risk of Acute Lymphoblastic Leukemia in Native Americans from Brazilian Amazonia" Journal of Personalized Medicine 12, no. 6: 856. https://doi.org/10.3390/jpm12060856

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop